Observational data demonstrated a possible association between semaglutide and NAION, Gerchman continued
Key findings of the study include: Patients initiating GLP-1R agonists ( n = 448), SGLT-2 inhibitors ( n = 112), DPP-4 inhibitors ( n = 435), sulfonylureas ( n = 2,253), or basal insulin ( n = 2,692) were identified
doi: 10.1002/art.34397 54 MukhopadhyayKDeSKunduSGhoshPChatterjeeSChatterjeeM
This effect is achieved through the activation of signaling pathways such as the ERK1/2, PI3K/AKT, and cAMP/PKA/-cat-Ser675 pathways, which are mediated by GLP-1RAs
[11] [12] However, prescribing these medications off-licence purely for weight management remains controversial and is generally not supported by NHS commissioning policies
Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains